z-logo
open-access-imgOpen Access
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement
Author(s) -
Gianluca Cristiano,
Jacopo Nanni,
Chiara Sartor,
Sarah Parisi,
Giovanni Marconi,
Francesco Barbato,
Mario Arpinati,
Francesca Bonifazi,
Antonio Curti,
Michèle Cavo,
Stefania Paolini,
Cristina Papayannidis
Publication year - 2021
Publication title -
acta haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 56
eISSN - 1421-9662
pISSN - 0001-5792
DOI - 10.1159/000516003
Subject(s) - ponatinib , medicine , philadelphia chromosome , myeloid leukemia , hematopoietic stem cell transplantation , chromosomal translocation , leukemia , cancer research , transplantation , chemotherapy , blinatumomab , tyrosine kinase inhibitor , acute lymphocytic leukemia , lymphoblastic leukemia , oncology , dasatinib , imatinib , biology , cancer , genetics , gene
T-cell acute lymphoblastic leukemia (T-ALL) is a rare entity in the adult acute leukemia setting. Translocation (9;22)(q34;q11) and BCR-ABL1 rearrangement are occasionally found in T-ALL and have been reported in no more than 100 cases in the literature (most of which are chronic myeloid leukemia blast crisis). Here, we report the remarkable effectiveness of third-generation tyrosine-kinase inhibitor ponatinib in obtaining hematological and metabolic remission, in a patient with Philadelphia chromosome-positive de novo T-ALL and outcomes of a therapeutic strategy containing chemotherapy intensification, nelarabine, and allogeneic hematopoietic stem cell transplantation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom